<DOC>
	<DOCNO>NCT02719197</DOCNO>
	<brief_summary>The primary purpose first-in-man study investigate whether new drug neurological disorder safe well-tolerated administer orally healthy male adult</brief_summary>
	<brief_title>First-in-man Study Single Ascending Dose New Drug Neurological Disorders</brief_title>
	<detailed_description />
	<mesh_term>Nervous System Diseases</mesh_term>
	<criteria>Signed informed consent Healthy basis physical examination , electrocardiogram laboratory test . A subject female partner childbearing potential pregnant partner agree use condom combination spermicide condom , respectively , screen , entire study , least 3 month ( last ) study drug intake Body mass index ( BMI ) 18.0 29.9 kg/m2 ( inclusive ) screen Day 1 . Systolic blood pressure ( SBP ) 100140 mmHg , diastolic blood pressure ( DBP ) 5090 mmHg , pulse rate 5090 bpm ( inclusive ) , measure 5 min supine position screen Day 1 . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study treatment Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction Any cardiac condition illness potential increase cardiac risk subject base medical history , physical examination , electrocardiogram ( ECG ) evaluations Any circumstance condition , , opinion Investigator , may affect full participation study compliance protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>